Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Acorda writes off $363M drug, axing PhIII Parkinson’s drug in the wake of 5 patient deaths
Acorda writes off $363M drug, axing PhIII Parkinson’s drug in the wake of 5 patient deaths
Acorda writes off $363M drug, axing PhIII Parkinson’s drug in the wake of 5 patient deaths
Submitted by
admin
on November 20, 2017 - 9:31am
Source:
Endpoints
News Tags:
Acorda Therapeutics
Parkinson's Disease
tozadenant
clinical trials
Headline:
Acorda writes off $363M drug, axing PhIII Parkinson’s drug in the wake of 5 patient deaths
Do Not Allow Advertisers to Use My Personal information
